Evidence map›Paper›PMID 10456659›Full record

ArticleMedical oncology (Northwood, London, England)1999

Transforming growth factor-beta and multidrug resistance in chronic lymphocytic leukemia.

W R Friedenberg, S A Salzman, S M Phan, J K Burmester

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

W R FriedenbergDepartment of Hematology/Oncology, Marshfield Clinic, Wisconsin, USA.
S A Salzman
S M Phan
J K Burmester
Marshfield Clinic · USMarshfield Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with chronic lymphocytic leukemia (CLL) frequently respond to initial treatment, but then become resistant to chemotherapy. Studies have shown one important cause of chemotherapeutic resistance to be multidrug resistance (MDR). To investigate the potential role of MDR and transforming growth factor-beta (TFG-beta), a potent growth inhibitor of B lymphocytes, in the development of chemotherapeutic resistance in CLL, we evaluated 22 CLL patients for loss or mutation of TGF-beta receptors (TbetaR), plasma TGF-beta1 levels, and expression of MDR1 mRNA. Receptor crosslinking and immunoprecipitation experiments did not demonstrate loss of TbetaRs in any patients studied. No relationship between plasma TGF-beta1 levels and expression of MDR1 mRNA was seen. Correlation of plasma TGF-beta1 levels to disease stage revealed a consistent decline in plasma TGF-beta1 levels with advancing disease stage (P = 0.031).

Indexed as

Drug Resistance, MultipleAdultAgedAged, 80 and overAntineoplastic AgentsDisease ProgressionDNA Mutational AnalysisFemaleGene ExpressionGenes, MDRHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedPrecipitin TestsReceptors, Transforming Growth Factor betaAntineoplastic AgentsReceptors, Transforming Growth Factor betaTransforming Growth Factor beta

Identifiers

PMID10456659
OpenAlexW2187441346

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.